

**МІНІСТЕРСТВО ОХОРОНИ ЗДОРОВ'Я УКРАЇНИ
ТЕРНОПІЛЬСЬКИЙ НАЦІОНАЛЬНИЙ МЕДИЧНИЙ
УНІВЕРСИТЕТ ІМЕНІ І. Я. ГОРБАЧЕВСЬКОГО**



**НАУКОВО-ТЕХНІЧНИЙ ПРОГРЕС І ОПТИМІЗАЦІЯ
ТЕХНОЛОГІЧНИХ ПРОЦЕСІВ СТВОРЕННЯ
ЛІКАРСЬКИХ ПРЕПАРАТІВ**

**МАТЕРІАЛИ VIII НАУКОВО-ПРАКТИЧНОЇ КОНФЕРЕНЦІЇ
З МІЖНАРОДНОЮ УЧАСТЮ
*23–24 вересня 2020 р.***

Тернопіль
ТНМУ
«Укрмедкнига»
2020

УДК 615.1

Редакційна колегія:

проф. Кліщ І.М., проф. Грошовий Т.А., проф. Фіра Л.С., доц. Вронська Л.В.,
доц. Демчук М.Б., доц. Чубка М.Б., ас. Стечишин І.П. ас. Дуб А.І.,
ас. Павлюк Б.В.

Науково-технічний прогрес і оптимізація технологічних процесів
створення лікарських препаратів : матеріали VII наук.-практ. конф. з міжнар.
участю (Тернопіль, 23-24 вересня 2020 р.). – Тернопіль : ТНМУ, 2020. – 320 с.

*Усі матеріали збірника подаються в авторській редакції. Відповідальність
за представлені результати досліджень несуть автори тез.*

market share, but by the end of the studied period this figure reached 19%. This group was formed mainly due to the volumes of the following international nontrade name (INN) antidepressants: sertraline, venlafaxine, mirtazapine, escitalopram, tianeptine, pirlindol and milnacipran. As of 2018, the assortment was formed only by escitalopram, mirtazapine, sertraline and venlafaxine.

Regarding the group of antidepressants with a "stimulating" effect, by the end of the study period they occupied 37% of the market share. This group mainly included the following drugs, such as paroxetine, fluoxetine, imipramine. But by 2018, this group consisted only of paroxetine and fluoxetine, respectively.

Conclusions

45% of the market share by clinical classification is mainly antidepressants with sedation. In general, the market can speak of a "meager" supply and unoccupied market niches. Above this kind of classification regarding the pharmacological effect of antidepressants is important for understanding the etiology and characteristics of the onset, course of depression, which prevailed or predominates in the allotted period of time, for further planning of marketing activities, as well as the formation of the production and trade assortment of distributors by supplying the necessary drugs in optimal volumes.

PHARMACOECONOMIC STUDIES OF CARDIAC DRUGS

I. V. Sakhanda

Bogomolets National Medical University, Kyiv, Ukraine
sahanda.ivanna@ukr.net

The main manifestations of the other trend are the use of different medical interventions without proper indications, the use of outdated, ineffective and dangerous drugs and technologies. There is a stable trend of increasing the number of cardiovascular diseases in Ukraine, especially hypertension and ischemic heart disease. In the structure of the total morbidity, cardiovascular diseases take the second place and are one of the main causes of disability, disability and mortality of the population of Ukraine. The result of the analysis of consumers' motivations when choosing herbal drugs for the treatment of cardiovascular disease (CVD) indicates the need to provide doctors and pharmacy workers with extended information on their use, as well as the use of modern information retrieval systems. Motivating factors in the purchase of drugs of plant origin by consumers are mainly their cost (92,6 %), therapeutic efficacy (80,7 %) and the absence of adverse reactions (75,2 %).

Another negative feature of the treatment of CVD at the present stage is the lack of methodology and practice of optimal choice of drugs in terms of their value and effectiveness. This is facilitated by the aggressive marketing policies of the manufacturing companies, on the one hand, and the lack of systematic research into the rational use of medicines with poor motivation in practitioners. All this leads to a significant overestimation of the cost of treatment. In the current situation, there are

contradictions between the need to introduce new drugs into clinical practice and their affordability. Based on the research, the main provisions of the concept of pharmaceutical care for CVD patients in modern conditions, the essence of which is to use at all stages of the treatment process an effective range of drugs, pharmaceutical services and constant interaction of doctor, patient and pharmacist.

Therefore, the cost of therapy increases, the patient as a whole needs to know how justified the costs of treatment with a particular drug and how reasonable are the costs of the additional benefits of more expensive drugs.

PROSPECTS FOR THE DEVELOPMENT OF ANTIBACTERIAL PACKAGING BASED ON BEESWAX

Yu.V. Yudina, I.M. Grybnik, I.A. Zhuravel
Kharkiv medical academy of postgradual education
Eco3557@gmail.com

Background. The problems of plastic pollution have got global scales. Every year about 13 million tons of plastic pollute the oceans and lands, harming biodiversity and the economy. In addition, it is proven that under certain conditions plastic releases toxic compounds such as aldehydes, ketones, alcohols, peroxides, acids and their salts, as well as dust, which entering the human body adversely affect his health, having an irritating and allergenic effect.

To reduce the growth of plastic waste, many countries are imposing restrictions on the use of plastic bags, plastic containers and packaging, and Ukraine is among them. Ukraine has adopted a Strategy for State Environmental Policy until 2030, which should be a change in the country's environmental course to European. And on November 13, 2019, the Parliament adopted in the first reading the draft law №2051-1 "On limitation of plastic bags turnover in Ukraine", which will come into force on January 1, 2022 and impose severe restrictions on the use of plastic packaging.

Therefore, the urgent task of scientists and manufacturers is to find new alternative types of packaging that will be environmentally friendly and have a number of useful properties in relation to the product.

The aim is to study the possibility and prospects for the development of antibacterial packaging based on beeswax technology.

Materials and methods of research. As the object of given study was choose packaging based on beeswax, as well as the analysis of existing technologies.

Results and discussion. Recent trends in the EU packaging market are showing interest in green packaging, packaging made from recyclable materials, secondary materials and biodegradable materials. But some plastics sold under biodegradable brands were not in fact biodegradable, and those plastics that were in fact “degradable microorganisms” had a very high cost or did not have the necessary performance characteristics.